Scinovex
articleTop 1% cited

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

The Lancet · 2001 · Vol. 358(9286) · pp. 958–965
Michael P. MannsJohn G. McHutchisonStuart C. GordonVinod K. RustgiMitchell L. ShiffmanRobert ReindollarZachary GoodmanKenneth KouryMei–Hsiu LingJanice K. Albrecht
Hepatitis C virus researchLiver Disease Diagnosis and TreatmentHepatitis B Virus StudiesRibavirinMedicineGastroenterologyInternal medicinePeginterferon alfa-2aInterferon alfaHepatitis CAlpha interferonInterferonChronic hepatitis

MeSH terms

Interferon alpha-2AdultAgedDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleGenotypeHumansMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRibavirinRNA, Viral

Funding

  • Massachusetts General Hospital
Citations
6,046
FWCI
158.98
field-weighted impact
References
22
Percentile
100%
vs. same field & year
Citations per year
Related articles
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
New England Journal of Medicine · 2002 · 6,389 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.